AIMS: Malignant rhabdoid tumours (MRTs) are highly aggressive malignancies of early infancy characterized by inactivation of SMARCB1, a core member of the SWI/SNF chromatin-remodelling complex. The aim of this study was to explore the status of multiple key subunits of the SWI/SNF complex in MRTs. METHODS AND RESULTS: We screened the key subunits of the SWI/SNF complex, including SMARCB1, SMARCA2, PBRM1, SMARCA4, and ARID1A, in four MRTs by immunohistochemistry, sequencing, and fluorescence in-situ hybridization (FISH). Complete loss of SMARCB1, SMARCA2 and PBRM1 expression and corresponding mutations in the same genes were observed in all cases. The mutations included seven missense, three same-sense, four frameshift and two truncating mutations. FISH revealed heterozygous deletion of SMARCB1 in one case, and monoploidy of chromosome 22, which harbours SMARCB1, in another case. Furthermore, trisomy of chromosome 9, which harbours SMARCA2, was observed in two cases. Abnormality of PBRM1 was not found in any case. CONCLUSIONS: We report, for the first time, co-inactivation and frequent mutations of SMARCB1, SMARCA2 and PBRM1 in MRTs. Multiple subunit abnormalities of the SWI/SNF complex potentially act together to contribute to the tumorigenesis of MRTs, which provides unique insights into this disease.
AIMS: Malignant rhabdoid tumours (MRTs) are highly aggressive malignancies of early infancy characterized by inactivation of SMARCB1, a core member of the SWI/SNF chromatin-remodelling complex. The aim of this study was to explore the status of multiple key subunits of the SWI/SNF complex in MRTs. METHODS AND RESULTS: We screened the key subunits of the SWI/SNF complex, including SMARCB1, SMARCA2, PBRM1, SMARCA4, and ARID1A, in four MRTs by immunohistochemistry, sequencing, and fluorescence in-situ hybridization (FISH). Complete loss of SMARCB1, SMARCA2 and PBRM1 expression and corresponding mutations in the same genes were observed in all cases. The mutations included seven missense, three same-sense, four frameshift and two truncating mutations. FISH revealed heterozygous deletion of SMARCB1 in one case, and monoploidy of chromosome 22, which harbours SMARCB1, in another case. Furthermore, trisomy of chromosome 9, which harbours SMARCA2, was observed in two cases. Abnormality of PBRM1 was not found in any case. CONCLUSIONS: We report, for the first time, co-inactivation and frequent mutations of SMARCB1, SMARCA2 and PBRM1 in MRTs. Multiple subunit abnormalities of the SWI/SNF complex potentially act together to contribute to the tumorigenesis of MRTs, which provides unique insights into this disease.
Authors: Thomas Januario; Xiaofen Ye; Russell Bainer; Bruno Alicke; Tunde Smith; Benjamin Haley; Zora Modrusan; Stephen Gould; Robert L Yauch Journal: Proc Natl Acad Sci U S A Date: 2017-10-30 Impact factor: 11.205
Authors: Abbas Agaimy; Arndt Hartmann; Cristina R Antonescu; Simion I Chiosea; Samir K El-Mofty; Helene Geddert; Heinrich Iro; James S Lewis; Bruno Märkl; Stacey E Mills; Marc-Oliver Riener; Thomas Robertson; Ann Sandison; Sabine Semrau; Roderick H W Simpson; Edward Stelow; William H Westra; Justin A Bishop Journal: Am J Surg Pathol Date: 2017-04 Impact factor: 6.394
Authors: Jennifer L Sauter; Rondell P Graham; Brandon T Larsen; Sarah M Jenkins; Anja C Roden; Jennifer M Boland Journal: Mod Pathol Date: 2017-06-23 Impact factor: 7.842
Authors: Hyun Deuk Cho; Jong Eun Lee; Hae Yoen Jung; Mee-Hye Oh; Ji-Hye Lee; Si-Hyong Jang; Kyung-Ju Kim; Sun Wook Han; Sung Yong Kim; Han Jo Kim; Sang Byung Bae; Hyun Ju Lee Journal: J Breast Cancer Date: 2015-12-23 Impact factor: 3.588
Authors: Andrew E Teschendorff; Shijie C Zheng; Andy Feber; Zhen Yang; Stephan Beck; Martin Widschwendter Journal: Genome Med Date: 2016-08-25 Impact factor: 11.117